Technology areas: Biotechnology & Pharmaceuticals • Chemistry & Materials
4 pending office actions • 3 art units • 4 examiners • 1 of 4 (25%) have an AI response strategy ready
Clearmind Labs Corp. currently faces 4 pending office actions within the Biotechnology & Pharmaceuticals technology area. These 4 actions are distributed among distinct examiners, ensuring that each application receives an independent review from a different professional. The prosecution effort is spread across 3 distinct art units, indicating that the company's biotech research touches on several different examination specialties within the patent office. This diversity in art units suggests that the company's pharmaceutical innovations are being evaluated for their unique contributions to different biological or chemical sub-fields.
JACKSON, SHAWQUIA is the busiest examiner for the company, currently overseeing 1 busiest examiner pending office action. Although JACKSON is labeled as the busiest, the workload is distributed among the examiners. This presence across 3 art units suggests that practitioners must prepare for different examination styles simultaneously to advance the biotechnology portfolio. Because the workload is not concentrated under a single individual, the company must maintain a flexible approach that addresses the specific technical concerns raised by each of the 4 examiners involved in the current cycle.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (50%) |
| Multi-statute (no §101) | 2 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| JACKSON, SHAWQUIA | 1 | 78.0% | -3.4% |
| CLARK, AMY LYNN | 1 | 39.2% | +31.1% |
| MOU, LIYUAN | 1 | 43.8% | +59.9% |
| HAWKINS, AMANDA SALATA | 1 | 15.4% | +40.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18701885 | 2-FLUORODESCHLOROKETAMINE FOR TREATMENT OF DEPRESSION, INCLUDING TREATMENT-RESISTANT DEPRESSION | CLARK, AMY LYNN | — |
| 18699185 | 5-MAPB OR 6-APB FOR USE IN DRUG-ASSISTED PSYCHOTHERAPY | MOU, LIYUAN | — |
| 17985979 | ALCOHOLIC BEVERAGE SUBSTITUTES | HAWKINS, AMANDA SALATA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18701885 | 2-FLUORODESCHLOROKETAMINE FOR TREATMENT OF DEPRESSION, INCLUDING TREATMENT-RESISTANT DEPRESSION | CLARK, AMY LYNN | — |
| 18699185 | 5-MAPB OR 6-APB FOR USE IN DRUG-ASSISTED PSYCHOTHERAPY | MOU, LIYUAN | — |
| 17985979 | ALCOHOLIC BEVERAGE SUBSTITUTES | HAWKINS, AMANDA SALATA | — |
| Art Unit | Apps |
|---|---|
| 1628 | 2 |
| 1629 | 1 |
| 1793 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18844341 | COMPOSITIONS COMPRISING MEAI AND N-ACYLETHANOLAMINES AND USES THEREOF | JACKSON, SHAWQUIA | 1629 | §103 | Non-Final OA | — | Pending | Sep 06, 2024 |
| 18701885 | 2-FLUORODESCHLOROKETAMINE FOR TREATMENT OF DEPRESSION, INCLUDING TREATMENT-RESISTANT DEPRESSION | CLARK, AMY LYNN | 1628 | §102§103§112 | Non-Final OA | — | Pending | Apr 16, 2024 |
| 18699185 | 5-MAPB OR 6-APB FOR USE IN DRUG-ASSISTED PSYCHOTHERAPY | MOU, LIYUAN | 1628 | §102§103§112 | Non-Final OA | — | Pending | Apr 05, 2024 |
| 17985979 | ALCOHOLIC BEVERAGE SUBSTITUTES | HAWKINS, AMANDA SALATA | 1793 | §103 | Non-Final OA | — | AI Ready | Nov 14, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialClearmind Labs Corp. has 4 pending office actions as of October 2026, spread across 3 art units and 4 examiners.
Shawquia Jackson has the most, with 1 of Clearmind Labs Corp.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
